Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?
Surrogate outcomes are not intrinsically beneficial to patients, but are designed to be easier and faster to measure than clinically meaningful outcomes. The use of surrogates as an endpoint in clinical trials...
BMC Medicine 2017 15:134
Published on: 21 July 2017